 | | Vol. 12.08 – 1 March, 2023 |
| |
|
|
| Investigators observed that polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) were remarkably enriched in the tumor microenvironment of CCL20-overexpressing cancer cell orthotopic allograft tumors.
[Signal Transduction and Targeted Therapy] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers identified a mitochondria-encoded circular RNA termed mcPGK1, mitochondrial circRNA for translocating phosphoglycerate kinase 1, which was highly expressed in liver tumor-initiating cells.
[Nature Communications] |
|
|
|
| Investigators introduced a nanomaterial-based approach to photothermally induce the differentiation of CSCs, termed “photothermal differentiation”, leading to the attenuation of cancer cell stemness, chemoresistance, and metastasis.
[Nano Letters] |
|
|
|
| Scientists designed a hyaluronic acid-coated siProminin2-loaded FeOOH nano-drug to accelerate ferroptosis of breast CSCs by simultaneously increasing iron ion content, inhibiting iron efflux, and scavenging glutathione.
[Acta Biomaterialia] |
|
|
|
| Researchers reported that Plexin B3 (PLXNB3) expression was increased in response to hypoxia and that PLXNB3 was a direct target gene of hypoxia-inducible factor 1 in human breast cancer cells.
[Cell Reports] |
|
|
|
| The authors pinpointed OPA1high with mitochondrial fusion as a metabolic feature of human lung CSCs, licensing their stem-like properties.
[JCI Insight] |
|
|
|
| The up-regulation of FBXL8 promoted the proliferation, invasion, and migration of colorectal cancer tumor cells and maintained the stem-cell characteristics of colorectal tumor cells.
[Clinical and Translational Medicine] |
|
|
|
| In order to target stem cells in ovarian cancer, scientists used the sortase reaction to site-specifically conjugate the potent cytotoxin monomethyl auristatin E and their co-receptors ZNRF3 and RNF43 via a protease-cleavable linker.
[Journal of Pharmacology and Experimental Therapeutics] |
|
|
|
| Investigators evaluated the effect of the tetrose saccharide, erythrose, a neuroleukin inhibitor of invasiveness and drug sensitization in glioblastoma stem cells.
[Medical Oncology] |
|
|
|
|
| The authors review up-to-date knowledge of the relationship between m6A modulation and drug resistance and discuss the regulation of m6A modulation in epithelial-mesenchymal transition and CSCs.
[Heliyon] |
|
|
|
|
| Tachyon Therapeutics, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $7.1 million grant to support a Phase I clinical study of TACH101 in patients with advanced solid tumors.
[Tachyon Therapeutics, Inc.] |
|
|
|
|
| April 23 – 28, 2023
Cancun, Mexico |
|
|
|
|
|
| | Albert Einstein College of Medicine – New York, New York, United States |
|
|
|
| | Weill Cornell College of Medicine – New York, New York, United States |
|
|
|
| | Penn Medicine – Philadelphia, Pennsylvania, United States |
|
|
|
| | The Henry Ford Health System – Detroit, Michigan, United States |
|
|
|
| | The University of Melbourne – Melbourne, Australia |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
